@article{686c4fce53b2497cb692bc0e851b8a5f,
title = "Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial",
abstract = "Objectives: This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Background: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrated that in moderate- and high-risk ACS patients undergoing PCI, bivalirudin alone compared to unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor resulted in less major bleeding and similar ischemic outcomes at 30 days.",
keywords = "bivalirudin, enoxaparin, unfractionated heparin",
author = "White, \{Harvey D.\} and Ohman, \{E. Magnus\} and Lincoff, \{A. Michael\} and Bertrand, \{Michel E.\} and Antonio Colombo and McLaurin, \{Brent T.\} and Cox, \{David A.\} and Pocock, \{Stuart J.\} and Ware, \{James A.\} and Manoukian, \{Steven V.\} and Lansky, \{Alexandra J.\} and Roxana Mehran and Moses, \{Jeffrey W.\} and Stone, \{Gregg W.\}",
note = "Funding Information: Dr. White has received consulting fees and lecture fees from The Medicines Company and Sanofi-Aventis and received grantsupport from The Medicines Company, Sanofi-Aventis, Proctor \& Gamble, ScheringPlough, and Eli Lilly Co. Dr. Ohman has received consulting fees from The Medicines Company, Sanofi-Aventis, Liposcience, Inovise Medical, Response Biomedical, and Savacor; equity interests in Medtronic and Savacor; lecture fees from Schering-Plough, Bristol-Myers Squibb, and Datascope; and grant support from Schering-Plough, Bristol-Myers Squibb, and Berlex. Dr. Lincoff has received lecture fees from The Medicines Company and grant support from The Medicines Company and Centocor. Dr. Stone has received consulting fees from The Medicines Company and lecture fees from The Medicines Company and Nycomed. Dr. Cox has received lecture fees from The Medicines Company. Dr. Pocock has received consulting fees from The Medicines Company. Dr. Ware has received consulting fees from The Medicines Company, Biogen, InfraReDx, and Schering-Plough. Dr. Manoukian has received consulting fees from The Medicines Company, Bristol-Myers Squibb, Schering-Plough, and Sanofi-Aventis, and lecture fees from The Medicines Company and Nycomed. Dr. Mehran has received lecture fees from The Medicines Company, Cordis, and Boston Scientific. Dr. Moses has received consulting fees from Johnson \& Johnson and is on the Speakers' Bureau for AstraZeneca. ",
year = "2008",
month = sep,
day = "2",
doi = "10.1016/j.jacc.2008.05.036",
language = "English",
volume = "52",
pages = "807--814",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier Inc.",
number = "10",
}